vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
vTv Therapeutics Inc.NASDAQ: VTVT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $8.98M rose 217.2% year over year, ahead of the +104.7% change in trailing-twelve-month research & development. Sequentially, it rose 129.7% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +217.2% holds above the trailing-twelve-month pace of +104.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.86M USD
- Year-over-year change
- +54.7%
- 4-year CAGR
- +7.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.86M | +54.7% |
| FY2024 | 2024-12-31 | 11.55M | -15.1% |
| FY2023 | 2023-12-31 | 13.6M | +10.0% |
| FY2022 | 2022-12-31 | 12.36M | -7.3% |
| FY2021 | 2021-12-31 | 13.32M | — |
Research & Development vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 research & development of $24.01M is the 4th highest of the 9 companies compared; the peer median is $18.97M.
- Its year-over-year change of +104.7% is the 3rd highest of 9, against a peer median of -29.1%.
- Research & development amounts to 65.2% of revenue for VTVT, versus a peer median of 171.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $6.96B | +137771.3% | +529.2% | — | |
| LTM Jun 2026 | $32.91M | -39.6% | -5.9% | 156.7% | |
| LTM Mar 2026 | $24.01M | +104.7% | +13.1% | 65.2% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $16.69M | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $10.72M | +1.7% | +6.8% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| Peer median (excluding VTVT) | $18.97M | -29.1% | +0.5% | 171.8% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — |
| Research & Development | 13.32M | 12.36M | 13.6M | 11.55M | 17.86M |
| Selling, General & Admin | 12.34M | 12.2M | 11.91M | 13.65M | 14.95M |
| Operating Expenses | 25.67M | 24.56M | 25.5M | 25.2M | 32.81M |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| EBITDA | (17.52M) | (24.77M) | (25.86M) | (22.52M) | (31.06M) |
| EBITDA Margin | -437.3% | -1227.3% | — | -2214.0% | — |
| Operating Income | (21.66M) | (22.54M) | (25.5M) | (24.18M) | (32.81M) |
| Operating Margin | -540.9% | -1116.9% | — | -2377.6% | — |
| Interest Income | 1K | 352K | 472K | 1.57M | 1.87M |
| Interest Expense | 12K | 15K | 13K | 0 | 6K |
| Other Income / Expenses | 4.05M | (2.33M) | (464K) | 1.58M | 1.73M |
| Income Before Tax | (17.62M) | (24.87M) | (25.97M) | (22.61M) | (31.08M) |
| Pre-Tax Margin | -439.9% | -1232.6% | — | -2222.7% | — |
| Income Tax Expense | 115K | 200K | 0 | 100K | 0 |
| Net Income | (12.99M) | (19.16M) | (20.25M) | (18.46M) | (26.97M) |
| Net Margin | -324.3% | -949.7% | — | -1815.3% | — |
| EPS (Basic) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| EPS (Diluted) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| Weighted Avg Shares | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
| Weighted Avg Shares (Diluted) | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.